Positive topline results with GLPG1972 in osteoarthritis patients
Galapagos NV - American Depositary Shares (GLPG)
Last galapagos nv - american depositary shares earnings: 10/24 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
glpg.com/company-overview
Company Research
Source: GlobeNewswire
Mechelen, Belgium; 7 January 2018, 22.00 CET - Galapagos NV (Euronext & NASDAQ: GLPG) reports positive preliminary topline results with a Phase 1b study in osteoarthritis (OA) patients in the United States. Galapagos evaluated GLPG1972 in a randomized, placebo-controlled, double-blind Phase 1b study in 30 patients aged 50 to 75 years with diagnosis of knee and/or hip osteoarthritis, in the United States. Patients were given one of three doses of GLPG1972 or placebo for a total of 4 weeks, with a 3 week follow-up period. Primary objectives were to evaluate safety, tolerability, and pharmacokinetics of GLPG1972 in patients. A secondary objective was to measure the reduction of ARGS neoepitope, an important cartilage breakdown biomarker. The mechanism of action of GLPG1972, which targets a cartilage degrading enzyme called ADAMTS-5, was confirmed in two animal models. An earlier Phase 1 study in healthy volunteers met all its safety and pharmacokinetic targets and also demons
Show less
Read more
Impact Snapshot
Event Time:
GLPG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GLPG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GLPG alerts
High impacting Galapagos NV - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GLPG
News
- Galapagos NV (NASDAQ: GLPG) had its "equal weight" rating re-affirmed by analysts at Morgan Stanley. They now have a $38.00 price target on the stock.MarketBeat
- Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024 [Yahoo! Finance]Yahoo! Finance
- Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024GlobeNewswire
- Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders' Meetings [Yahoo! Finance]Yahoo! Finance
- Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ MeetingsGlobeNewswire
GLPG
Earnings
- 5/4/23 - Beat
GLPG
Sec Filings
- 4/8/24 - Form 6-K
- 3/29/24 - Form 6-K
- 3/29/24 - Form 6-K
- GLPG's page on the SEC website